Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www. cpicpgx.
org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB …

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation …

There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are
used to prevent ischemic outcomes in common diseases such as coronary and peripheral …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …